What is Myeloid Therapeutics's official website?

Myeloid Therapeutics's website is myeloidtx.com

How many employees are working in Myeloid Therapeutics right now?

Myeloid Therapeutics has 41 employees.

What is Myeloid Therapeutics's industry?

Myeloid Therapeutics's industry is Biotechnology

Who are Myeloid Therapeutics's top competitors?

Myeloid Therapeutics's top competitors are , , , , , ,

Myeloid Therapeutics company information, Employees & Contact Information

Explore related pages

Myeloid Therapeutics email format Myeloid Therapeutics management contacts

Related company profiles:

At Myeloid, we have applied our extensive knowledge of advanced gene and cell therapies to build novel platform technologies that harness the innate abilities of myeloid cells. We have translated the learnings from our backgrounds and novel platform to create a clinical-stage, mRNA-immunotherapy pipeline focused on breakthrough therapies for cancer. We invite you to join us on this journey – patients are waiting.

Employees: 41
Address: 300 Technology Sq,
Industry: Biotechnology
Website: myeloidtx.com
HQ: Cambridge, Massachusetts
Competitors: Tessera Therapeutics, Capstan Therapeutics, Umoja Biopharma, Orna Therapeutics, Beam Therapeutics, Nanocell Therapeutics, Interius BioTherapeutics, EsoBiotec, Kelonia Therapeutics, Carisma Therapeutics.

Myeloid Therapeutics Questions

News

Myeloid Therapeutics Unveils First-in-Human In Vivo mRNA CAR Data, Marking a Breakthrough in RNA-Based Immuno-Oncology at the 2025 ASCO Annual Meeting - PR Newswire

Myeloid Therapeutics Unveils First-in-Human In Vivo mRNA CAR Data, Marking a Breakthrough in RNA-Based Immuno-Oncology at the 2025 ASCO Annual Meeting PR Newswire

In vivo programmed myeloid cells expressing novel chimeric antigen receptors show potent anti-tumor activity in preclinical solid tumor models - Frontiers

In vivo programmed myeloid cells expressing novel chimeric antigen receptors show potent anti-tumor activity in preclinical solid tumor models Frontiers

Myeloid Appoints Robert Hofmeister, Ph.D., as Chief Scientific Officer - citybiz

Myeloid Appoints Robert Hofmeister, Ph.D., as Chief Scientific Officer citybiz

Myeloid Therapeutics Announces SITC 2024 Oral Presentation on MT-303, the First in vivo GPC3 Targeting mRNA CAR in Human Studies for Advanced Hepatocellular Carcinoma (HCC) - PR Newswire

Myeloid Therapeutics Announces SITC 2024 Oral Presentation on MT-303, the First in vivo GPC3 Targeting mRNA CAR in Human Studies for Advanced Hepatocellular Carcinoma (HCC) PR Newswire

Myeloid Therapeutics Launches with Over $50 Million in Financing and Two Clinical Trials - PR Newswire

Myeloid Therapeutics Launches with Over $50 Million in Financing and Two Clinical Trials PR Newswire

Myeloid Therapeutics to Showcase In Vivo CAR Data and its Diverse mRNA Platform at AACR - PR Newswire

Myeloid Therapeutics to Showcase In Vivo CAR Data and its Diverse mRNA Platform at AACR PR Newswire

Myeloid Therapeutics Initiates Patient Dosing with MT-303, a Novel GPC3 Targeting RNA CAR, in Phase 1 Study for Advanced Hepatocellular Carcinoma (HCC) - PR Newswire

Myeloid Therapeutics Initiates Patient Dosing with MT-303, a Novel GPC3 Targeting RNA CAR, in Phase 1 Study for Advanced Hepatocellular Carcinoma (HCC) PR Newswire

New South Wales Government (NSW) Partner, Myeloid Therapeutics, Initiates Patient Dosing with MT-302 in Phase 1 Study at Clinical Site in Australia - PR Newswire

New South Wales Government (NSW) Partner, Myeloid Therapeutics, Initiates Patient Dosing with MT-302 in Phase 1 Study at Clinical Site in Australia PR Newswire

Myeloid Therapeutics Announces $73 Million Financing to Advance mRNA-based Immunotherapy Pipeline - PR Newswire

Myeloid Therapeutics Announces $73 Million Financing to Advance mRNA-based Immunotherapy Pipeline PR Newswire

Companies like Myeloid Therapeutics

Top Myeloid Therapeutics Employees

Daniel Geffken

Founder And Managing Director At…

Cambridge, Massachusetts, United States, United States

View
Kenanova Vania

Senior Director At Myeloid…

Cambridge, Massachusetts, United States, United States

View

5
hotmail.com, novartis.com, gmail.com, tcr2.com, agenusbio.com

2 +162637XXXXX
Curtis Demick

Chief People Officer At Myeloid…

Boston, Massachusetts, United States, United States

View

3
aol.com, ariad.com, goldfinchbio.com

2 +161762XXXXX
Mark Velleca

Biotech Executive

Washington, District Of Columbia, United States, United States

View

5
stridebio.com, yahoo.com, g1therapeutics.com, cellulargenomics.com, cgipharma.com

4 +191921XXXXX

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles

Get direct phone numbers & mobile contacts

Access company data & employee information

Works directly on LinkedIn - no copy/paste needed

Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Learn More

How It Works

Get a Free Account

Search the #1 Contact Database

Get contact details of over 750M+ profiles across 60M companies – all with industry-leading accuracy. Sales Navigator and Recruiter users, try out our Email Finder Extension.

Use our AI-Powered Email Finder

Find business and personal emails and mobile phone numbers with exclusive coverage across niche job titles, industries, and more for unparalleled targeting. Also available via our Contact Data API.

Have a look at Aeroleads Data

Browse our Data

Company Search

a b c d e f g h i j k l m n o p q r s t u v w x y z

Profile Search

a b c d e f g h i j k l m n o p q r s t u v w x y z

List Search

a b c d e f g h i j k l m n o p q r s t u v w x y z

Myeloid Therapeutics company information, Employees & Contact Information

Explore related pages

Company Details

Myeloid Therapeutics Questions

What is Myeloid Therapeutics's official website?

What is Myeloid Therapeutics's LinkedIn profile?

How many employees are working in Myeloid Therapeutics right now?

What is Myeloid Therapeutics's industry?

What are Myeloid Therapeutics's top competitors?

What are Myeloid Therapeutics's categories?

News

Myeloid Therapeutics Unveils First-in-Human In Vivo mRNA CAR Data, Marking a Breakthrough in RNA-Based Immuno-Oncology at the 2025 ASCO Annual Meeting - PR Newswire

In vivo programmed myeloid cells expressing novel chimeric antigen receptors show potent anti-tumor activity in preclinical solid tumor models - Frontiers

Myeloid Appoints Robert Hofmeister, Ph.D., as Chief Scientific Officer - citybiz

Myeloid Therapeutics Announces SITC 2024 Oral Presentation on MT-303, the First in vivo GPC3 Targeting mRNA CAR in Human Studies for Advanced Hepatocellular Carcinoma (HCC) - PR Newswire

Myeloid Therapeutics Launches with Over $50 Million in Financing and Two Clinical Trials - PR Newswire

Myeloid Therapeutics to Showcase In Vivo CAR Data and its Diverse mRNA Platform at AACR - PR Newswire

Myeloid Therapeutics Initiates Patient Dosing with MT-303, a Novel GPC3 Targeting RNA CAR, in Phase 1 Study for Advanced Hepatocellular Carcinoma (HCC) - PR Newswire

New South Wales Government (NSW) Partner, Myeloid Therapeutics, Initiates Patient Dosing with MT-302 in Phase 1 Study at Clinical Site in Australia - PR Newswire

Myeloid Therapeutics Announces $73 Million Financing to Advance mRNA-based Immunotherapy Pipeline - PR Newswire

Companies like Myeloid Therapeutics

Capstan Therapeutics

Tessera Therapeutics

Nanocell Therapeutics

Carisma Therapeutics

Beam Therapeutics

Umoja Biopharma

Interius Biotherapeu...

Esobiotec

Kelonia Therapeutics

Orna Therapeutics

Top Myeloid Therapeutics Employees

Daniel Geffken

Founder And Managing Director At…

Kenanova Vania

Senior Director At Myeloid…

Curtis Demick

Chief People Officer At Myeloid…

Mark Velleca

Biotech Executive

Free Chrome Extension

Aero Online

Select data to include:

How It Works

Get a Free Account

Search the #1 Contact Database

Use our AI-Powered Email Finder

Have a look at Aeroleads Data